In the last trading session, 1.2 million Vir Biotechnology Inc (NASDAQ:VIR) shares changed hands as the company’s beta touched 1.15. With the company’s per share price at $9.10 changed hands at -$0.37 or -3.91% during last session, the market valuation stood at $1.25B. VIR’s last price was a discount, traded about -58.79% off its 52-week high of $14.45. The share price had its 52-week low at $6.56, which suggests the last value was 27.91% up since then.
Analysts gave the Vir Biotechnology Inc (VIR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.56. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended VIR as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Vir Biotechnology Inc’s EPS for the current quarter is expected to be -0.87.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Instantly VIR was in red as seen at the end of in last trading. With action -6.04%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 23.98%, with the 5-day performance at -6.04% in the red. However, in the 30-day time frame, Vir Biotechnology Inc (NASDAQ:VIR) is -14.39% down.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 54.5% from its current market value. According to analyst projections, VIR’s forecast low is 20 with 20 as the target high. To hit the forecast high, the stock’s price needs a -119.78% plunge from its current level, while the stock would need to soar -119.78% for it to hit the projected low.
Vir Biotechnology Inc (VIR) estimates and forecasts
Year-over-year growth is forecast to reach -20.34% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 8.14M. 4 analysts are of the opinion that Vir Biotechnology Inc’s revenue for the current quarter will be 13.66M. The company’s revenue for the corresponding quarters a year ago was 16.79M and 56.38M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -51.51%. The estimates for the next quarter sales put growth at -75.77%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.12%. The 2025 estimates are for Vir Biotechnology Inc earnings to increase by 15.42%, but the outlook for the next 5-year period is at 8.69% per year.
VIR Dividends
Vir Biotechnology Inc is expected to release its next quarterly earnings report in March.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 12.1482% or 16.43 million shares worth $146.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . With 5.9 shares estimated at $53.69 million under it, the former controlled 4.28% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.51% of the shares, roughly 3.46 shares worth around $31.5 million.
